Tag Archives: BIO Investor Forum

Perspective on Market Valuation for Biotech Drug Developers

Graph

Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% are working on molecular tools, diagnostics, biofuels, and other biotech endeavors. One question that is often asked with respect to drug-focused biotechs is: How big are they compared to traditional pharmaceutical companies? How many are valued as small start-ups vs large, or mid-size pharmas? It turns out that more than half the sector trades with a market valuation of less Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

Technology Transfer Symposium in San Francisco

5616315608_dd9b7a55dd_b

In the midst of turbulent economic times, and at a moment when the U.S. is looking to encourage technology job creation in the coming decade, an increasing number of public and private sector initiatives have been proposed to spur job creation. While the U.S. leads in the area of biotechnology, there is no guarantee that this competitive edge will continue.  Moreover, although the U.S. is more prolific in life science discoveries than any other single country in the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

BIO Investor Forum Company Snapshot: Syndax Pharmaceuticals

Syndax

Next up in our Company Snapshot segment for the BIO Investor Forum is another presenting company of the event. Hear from Joanna Horobin, President & CEO of Syndax Pharmaceuticals, Inc. Company Snapshot What are the short-term and long-term priorities for your company? Near-term we are focused on moving our lead product candidate, entinostat, in to a phase 3 clinical trial for post-menopausal women with estrogen receptor-positive (ER+) metastatic breast cancer (MBC). Long-term our goal is Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO Investor Forum Company Snapshot: GlobeImmune, Inc.

GlobeImmune

The BIO Investor Forum will be here before we know it, and we wanted to take the opportunity to highlight some of the companies who will be presenting at the 10th anniversary event. In our first Company Snapshot, hear from Timothy C. Rodell, the President and Chief Executive Officer of GlobeImmune, Inc.   Company Snapshot Q: What are the short-term and long-term priorities for your company? Short term – in oncology, completing the GI-4000 phase Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Fall Preview: Business Development Events

Banner

Now that the Business Forum and International Convention are behind us, our Business Development department has been gearing up for a very busy Fall schedule.   The Line-Up For our first Fall event, BIO returns to India for its 2nd annual BIO India International Partnering Conference September 21st and 22nd.  Last year’s conference attracted more than 400 attendees representing 220 companies, from 17 countries around the world, – who scheduled over 750 meetings.  We’ve had Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,